Investigation of cytochrome P450 polymorphisms, especially CYP2C9, and their role in the metabolism of non-steroidal anti-inflammatory drugs (NSAIDs).
Conditions
Interventions
There will be 2 groups already outlined (mutated to CYP2C9 and not mutated) with 15 participants each. All participants go through 3 stages and each consists of administering a single dose of NSAIDs o
Drug
Sponsors
Faculdade de Odontologia de Bauru
Faculdade de Odontologia de Bauru
Eligibility
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Good general health condition; absence of infection and inflammation; absence of systemic diseases; do not use any medicine that may alter the perception of pain or antidepressant, diuretic or anticoagulant medicines.
Exclusion criteria
Exclusion criteria: Patients with systemic diseases; patients with inflammation or infection; patients with a history of gastrointestinal bleeding or ulcerations; patients with cardiovascular, renal or liver disease; patients taking antidepressant, diuretic or anticoagulant medications; patients with a history of allergy to any other NSAIDs; pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Slower metabolization of non-steroidal anti-inflammatory drugs administered to individuals who have polymorphisms in the CYP2C9 gene compared to individuals without polymorphisms in CYP2C9. Metabolization will be assessed using mass spectrometry (LC MS/MS). Metabolization will be considered slower if it presents a statistical difference compared to the results of individuals without the polymorphism. | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlate the slower metabolization of individuals with polymorphisms in the CYP2C9 gene and less effective action of NSAIDs in terms of controlling inflammatory signals. Analysis of mass spectrometer data (LC MS / MS) and relevant clinical signs and symptoms, observed or reported. Outcome will be obtained by comparing the two groups and statistically relevant results.;Greater involvement of adverse effects with continuous use of NSAIDs (due to slower metabolism) in individuals with the polymorphic genotype of the CYP2C9 gene compared to those with wild genotype. Analysis of mass spectrometer data (LC MS / MS) and relevant clinical signs and symptoms, observed or reported. Outcome will be obtained by comparing the two groups and statistically relevant results. | — |
Countries
Brazil
Contacts
Public ContactAdriana Calvo
Faculdade de Odontologia de Bauru
Outcome results
None listed